| 1 |
NCT01785979 |
Withdrawn |
Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly |
- Hyper-reactive Malarial Splenomegaly
- Malaria
- Anaemia
|
- Drug: prednisone induction - chloroquine
- Drug: Chloroquine
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- composite clinical & immunological endpoint
- 3 months intermediate clinical cure
- 6 months intermediate clinical cure
- (and 3 more...)
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01785979 |
LiHMS |
LiHMS |
January 2016 |
February 2017 |
February 2017 |
February 7, 2013 |
November 13, 2015 |
|
- Lihir medical Centre
Londolovit, New ireland province, Papua New Guinea
|
| 2 |
NCT01907932 |
Completed |
Estimation of Spleen by Residents With VScan |
|
- Device: VScan Ultrasound (GE Healthcare, USA)
|
Interventional |
Not Applicable |
- University of British Columbia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- longitudinal measure of spleen in centimeters
- Diagnosis of spleen size
|
29 |
All |
Child, Adult, Senior |
NCT01907932 |
H13-01727 |
|
November 2013 |
May 2014 |
May 2014 |
July 25, 2013 |
April 14, 2017 |
|
- Vancouver Coastal Health (VCHRI/VCHA)
Vancouver, British Columbia, Canada
|
| 3 |
NCT01810419 |
Completed |
Ultrasound Estimation of Spleen Size |
|
- Device: Vscan Ultrasound (GE Healthcare, USA)
- Device: Conventional Ultrasound
|
Interventional |
Not Applicable |
- University of British Columbia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- longitudinal measure of spleen in centimeters
- Diagnosis of spleen size
- time to complete Vscan examination
|
16 |
All |
Child, Adult, Senior |
NCT01810419 |
H12-03055 |
|
March 2013 |
October 2013 |
March 2014 |
March 13, 2013 |
April 14, 2017 |
|
- Vancouver Coastal Health (VCHRI/VCHA)
Vancouver, British Columbia, Canada
|
| 4 |
NCT02386800 |
Recruiting |
CINC424A2X01B Rollover Protocol |
|
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
|
171 |
All |
18 Years and older (Adult, Senior) |
NCT02386800 |
CINC424A2X01B |
|
March 5, 2015 |
September 17, 2020 |
September 17, 2020 |
March 12, 2015 |
February 6, 2018 |
|
- Novartis Investigative Site
Darlinghurst, New South Wales, Australia - Novartis Investigative Site
St Leonards, New South Wales, Australia - Novartis Investigative Site
Herston, Queensland, Australia - (and 56 more...)
|
| 5 |
NCT00006148 |
Completed |
Spleen Size in Peripheral Blood Stem Cell Donors |
|
|
Observational |
|
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
49 |
All |
Child, Adult, Senior |
NCT00006148 |
000192
00-CC-0192 |
|
August 2000 |
|
June 2004 |
August 9, 2000 |
March 4, 2008 |
|
- Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, United States
|
| 6 |
NCT01948076 |
Completed
Has Results |
Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination |
- Splenomegaly
- Pleural Effusion
|
- Device: resident with GE vscan
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- General Electric
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Comparison of Diagnostic Ability of the Intervention Group's Ultrasound Exam to the Control Group's Physical Exam
- Improvement in Diagnostic Ability Within the Intervention Group
|
40 |
All |
24 Years to 35 Years (Adult) |
NCT01948076 |
2011P-002845 |
|
September 2012 |
November 2012 |
November 2012 |
September 23, 2013 |
March 19, 2015 |
February 26, 2015 |
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
| 7 |
NCT02463669 |
Recruiting |
The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department |
- Infectious Mononucleosis
- Splenomegaly
|
- Device: Point-of-care ultrasound
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Presence of splenomegaly (maximal splenic cranio-caudal length) on point-of-care ultrasound
|
280 |
All |
10 Years to 35 Years (Child, Adult) |
NCT02463669 |
POCUSIM01 |
|
April 2016 |
December 2018 |
December 2019 |
June 4, 2015 |
March 5, 2018 |
|
- CHU Sainte-Justine
Montreal, Quebec, Canada - Jewish General Hospital
Montreal, Quebec, Canada
|
| 8 |
NCT01692366 |
Completed |
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction as measured by MRI (or CT scan in subjects with contraindications for MRI). - Time Frame:
- Number of patients with Serious Adverse events using NCI CTCAE v4.03, clinical parameters and vital signs
- Measurements of SAR302503 pharmacokinetic endpoints including Cmax, Tmax, and AUC0-24
- (and 5 more...)
|
8 |
All |
20 Years and older (Adult, Senior) |
NCT01692366 |
ARD12888
U1111-1130-3710 |
|
November 2012 |
March 2014 |
March 2014 |
September 25, 2012 |
September 22, 2014 |
|
- Investigational Site Number 392010
Akita-Shi, Japan - Investigational Site Number 392002
Bunkyo-Ku, Japan - Investigational Site Number 392006
Bunkyo-Ku, Japan - (and 4 more...)
|
| 9 |
NCT02730884 |
Recruiting |
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia |
- Leukemia
- Myelofibrosis
- Anemia
- Splenomegaly
|
- Drug: Rigosertib
- Behavioral: Questionnaire
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Onconova Therapeutics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Spleen Volume
- Change in Anemia Response
- Symptoms Response
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT02730884 |
2014-0546
NCI-2016-00761 |
|
August 16, 2017 |
August 2022 |
August 2022 |
April 7, 2016 |
October 6, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 10 |
NCT01201655 |
Unknown † |
Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis |
- Liver Cirrhosis
- Carcinoma, Hepatocellular
- Splenomegaly
- Laparotomy
|
|
Observational |
|
- Xijing Hospital
- Fourth Military Medical University
- Health Science Center of Xi’an Jiaotong University
|
Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
|
5000 |
All |
20 Years to 90 Years (Adult, Senior) |
NCT01201655 |
chenyong |
|
January 2010 |
December 2012 |
December 2012 |
September 14, 2010 |
September 14, 2010 |
|
- Chen yong
Xi'an, Shaanxi, China
|
| 11 |
NCT02778425 |
Recruiting |
The Treatment of Hepatocirrhosis and Portal Hypertension |
|
|
Interventional |
Not Applicable |
- Yanjing Gao
- Shandong Provincial Hospital
- Jinan Military General Hospital
- Qilu Hospital of Shandong University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- recurrent rate of gastroesophageal varices
- rehaemorrhage ratio
- mortality
|
404 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02778425 |
201602-QILU |
|
February 2016 |
February 2019 |
February 2019 |
May 19, 2016 |
September 14, 2017 |
|
- Department of Gastroenterology,Qilu Hospital,Shandong University
Jinan, Shandong, China
|
| 12 |
NCT01437787 |
Completed |
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis |
|
- Drug: SAR302503
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Response Rate (RR), defined as the proportion of patients who have a ≥35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter
- Symptom Response Rate (SRR): Proportion of patients with ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score.
- OS (overall survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.
- (and 4 more...)
|
289 |
All |
18 Years and older (Adult, Senior) |
NCT01437787 |
EFC12153
2011-001897-25
U1111-1121-7170 |
JAKARTA |
December 2011 |
June 2014 |
June 2014 |
September 21, 2011 |
January 8, 2016 |
|
- Investigational Site Number 840014
Scottsdale, Arizona, United States - Investigational Site Number 840001
La Jolla, California, United States - Investigational Site Number 840012
La Jolla, California, United States - (and 98 more...)
|
| 13 |
NCT01420770 |
Completed |
Phase 2 Study of SAR302503 in Patients With Myelofibrosis |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The percent change in spleen volume based on MRI at the end of Cycle 3 relative to baseline
- The proportion of patients who achieve ≥35% reduction in spleen volume from baseline, to Cycle 6 end of cycle (EOC)
- The percent change in spleen volume based on MRI at Cycle 6 EOC compared to baseline
- (and 5 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01420770 |
ARD11936
U1111-1119-2965 |
|
August 2011 |
April 2014 |
April 2014 |
August 22, 2011 |
March 16, 2016 |
|
- Investigational Site Number 840001
San Francisco, California, United States - Investigational Site Number 840003
Ann Arbor, Michigan, United States - Investigational Site Number 840006
Rochester, Minnesota, United States - Investigational Site Number 840007
Canton, Ohio, United States
|
| 14 |
NCT03190915 |
Recruiting |
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia |
- Activating RAS Mutation
- Juvenile Myelomonocytic Leukemia
- Monosomy 7
- (and 4 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Trametinib
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response
- Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Pharmacokinetic parameters of trametinib
|
24 |
All |
2 Years to 21 Years (Child, Adult) |
NCT03190915 |
NCI-2017-00921
ADVL1521
U10CA180886 |
|
October 6, 2017 |
December 30, 2020 |
December 30, 2020 |
June 19, 2017 |
April 5, 2018 |
|
- Phoenix Childrens Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - Southern California Permanente Medical Group
Downey, California, United States - (and 27 more...)
|
| 15 |
NCT03010358 |
Recruiting |
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma |
- Anemia
- B-Cell Prolymphocytic Leukemia
- Fatigue
- (and 19 more...)
|
- Drug: Entospletinib
- Other: Laboratory Biomarker Analysis
- Biological: Obinutuzumab
- Other: Pharmacological Study
|
Interventional |
Phase 1
Phase 2 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CR defined as the proportion of subjects who achieve CR (Phase II)
- MTD and/or a recommended phase II dose as measured by the incidence of dose limiting toxicities assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase I)
- Event free survival (Phase II)
- (and 2 more...)
|
29 |
All |
19 Years and older (Adult, Senior) |
NCT03010358 |
STUDY00016140
NCI-2016-02029
P30CA069533 |
|
July 17, 2017 |
February 28, 2022 |
February 28, 2024 |
January 5, 2017 |
March 7, 2018 |
|
- University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States - Duke University Medical Center
Durham, North Carolina, United States - OHSU Knight Cancer Institute
Portland, Oregon, United States
|
| 16 |
NCT02948283 |
Active, not recruiting |
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia |
- Anemia
- Fatigue
- Fever
- (and 10 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Metformin Hydrochloride
- Other: Pharmacological Study
- (and 3 more...)
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.03
- Best overall response
- Clinical benefit response
- (and 5 more...)
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT02948283 |
16331
NCI-2016-01586 |
|
September 5, 2017 |
October 2018 |
October 2018 |
October 28, 2016 |
March 23, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States
|
| 17 |
NCT02048813 |
Active, not recruiting |
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
- Anemia
- Chronic Lymphocytic Leukemia
- Fatigue
- (and 8 more...)
|
- Drug: Cyclophosphamide
- Drug: Fludarabine Phosphate
- Drug: Ibrutinib
- (and 4 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Change in quality of life
- Overall survival (OS)
- (and 4 more...)
|
519 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02048813 |
NCI-2014-00118
E1912
ECOG-E1912
R01CA193541
U10CA180820
U10CA021115
U24CA196172 |
|
February 20, 2014 |
March 2, 2020 |
|
January 29, 2014 |
April 13, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 796 more...)
|
| 18 |
NCT01201174 |
Unknown † |
Hemolysis in Patients With Hereditary Spherocytosis (HS) |
|
- Other: fermented papaya preparation (FPP)
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC
- Hemolysis
|
15 |
All |
5 Years and older (Child, Adult, Senior) |
NCT01201174 |
SH-01CTIL |
|
September 2010 |
September 2011 |
September 2011 |
September 14, 2010 |
September 14, 2010 |
|
- Wolfsson Medical Center
Holon,, Israel,, Israel
|
| 19 |
NCT02417740 |
Recruiting |
Natural History of Noncirrhotic Portal Hypertension |
- Cystic Fibrosis
- Immunologic Deficiency Syndrome
- Turner Syndrome
- (and 2 more...)
|
|
Observational |
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To study the natural history of non cirrhotic portal hypertension.
|
400 |
All |
12 Years and older (Child, Adult, Senior) |
NCT02417740 |
150108
15-DK-0108 |
|
April 15, 2015 |
December 31, 2050 |
December 31, 2050 |
April 16, 2015 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 20 |
NCT00013689 |
Completed |
Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome |
- Autoimmune Disease
- Lymphoproliferative Disorder
|
- Drug: Fansidar (pyrimethamine and sulfadoxine)
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
8 |
All |
Child, Adult, Senior |
NCT00013689 |
010132
01-I-0132 |
|
March 2001 |
|
March 2003 |
March 29, 2001 |
March 4, 2008 |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
|
| 21 |
NCT03222609 |
Recruiting |
A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent Change in Splenic Volume from baseline
- Anemia Response Rate
- Change in Degree of Bone Marrow Fibrosis
- (and 5 more...)
|
34 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT03222609 |
M16-109
2017-001398-17 |
|
October 31, 2017 |
March 25, 2020 |
July 8, 2020 |
July 19, 2017 |
April 3, 2018 |
|
- UAB Comprehensive Cancer Cente
Birmingham, Alabama, United States - UCSD
La Jolla, California, United States - USC
Los Angeles, California, United States - (and 12 more...)
|
| 22 |
NCT02049450 |
Completed
Has Results |
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. |
|
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC)
- Percentage Change in Spleen Volume (cm3)
- Percentage Change in Mean Pre-transfusion Hemoglobin by 6 Week Time Intervals
- (and 3 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02049450 |
CINC424X2201
2013-002812-28 |
|
May 28, 2014 |
April 12, 2016 |
April 12, 2016 |
January 30, 2014 |
July 17, 2017 |
June 15, 2017 |
- Novartis Investigative Site
Athens, GR, Greece - Novartis Investigative Site
Milano, MI, Italy - Novartis Investigative Site
Palermo, PA, Italy - (and 4 more...)
|
| 23 |
NCT00605657 |
Completed
Has Results |
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) |
- ALPS
- Hypersplenism
- Lymphadenopathy
|
- Drug: Valproic Acid
- Procedure: CT Scan
- Procedure: Blood Sample
|
Interventional |
Phase 1
Phase 2 |
- Koneti Rao
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Response
- To Determine Whether the Treatment Alters, in Favorable Directions, Laboratory Markers of ALPS (e.g., Number of DNT Cells, Immunoglobin Levels, Vitamin B12 Levels, IL-10 Levels, Autoantibody Titers, Fas Mediated Apoptosis)
|
6 |
All |
2 Years to 70 Years (Child, Adult, Senior) |
NCT00605657 |
080053
08-I-0053 |
|
January 2008 |
September 2011 |
September 2011 |
January 31, 2008 |
March 21, 2013 |
March 21, 2013 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 24 |
NCT00065390 |
Completed |
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome |
- Autoimmune Disease
- Lymphatic Disease
- Lymphoproliferative Disorder
|
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
8 |
All |
Child, Adult, Senior |
NCT00065390 |
030248
03-I-0248 |
|
July 2003 |
|
June 2005 |
July 22, 2003 |
March 4, 2008 |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
|
| 25 |
NCT00754806 |
Completed |
Prospective Randomized Comparison of Clinical Results of Hand Assisted Laparoscopic Splenectomies and Open Splenectomies |
|
|
Observational |
|
|
Other |
- Time Perspective: Prospective
|
|
27 |
All |
Child, Adult, Senior |
NCT00754806 |
1687-2007 |
|
February 2007 |
October 2007 |
January 2008 |
September 18, 2008 |
September 18, 2008 |
|
|
| 26 |
NCT03165734 |
Recruiting |
Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib |
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Spleen volume
- Percentage of patients with CTCAE grade ≥3 cardiac AEs, CTCAE grade ≥3 hemorrhage AEs, CTCAE grade ≥4 thrombocytopenia toxicity, or CTCAE grade ≥4 anemia toxicity
|
105 |
All |
18 Years and older (Adult, Senior) |
NCT03165734 |
PAC203 |
|
June 26, 2017 |
December 1, 2018 |
March 1, 2019 |
May 24, 2017 |
March 23, 2018 |
|
- City of Hope
Duarte, California, United States - UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - Stanford Cancer Center, Palo Alto
Stanford, California, United States - (and 25 more...)
|
| 27 |
NCT02055781 |
Terminated |
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia |
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
|
- Drug: Pacritinib
- Drug: Best Available Therapy
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT02055781 |
PERSIST-2 (PAC326) |
PAC326 |
December 2013 |
August 2016 |
November 2016 |
February 5, 2014 |
December 16, 2016 |
|
- Mayo Clinic Arizona
Scottsdale, Arizona, United States - Arizona Clinical Research Center
Tucson, Arizona, United States - City of Hope
Duarte, California, United States - (and 119 more...)
|
| 28 |
NCT01773187 |
Terminated |
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis |
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
|
- Drug: Pacritinib
- Drug: Best Available Therapy
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy
- Symptomatic Efficacy
|
327 |
All |
18 Years and older (Adult, Senior) |
NCT01773187 |
PERSIST-1 (PAC325) |
|
December 2012 |
January 2015 |
June 2016 |
January 23, 2013 |
December 16, 2016 |
|
- CTI Investigational Site 10002
Scottsdale, Arizona, United States - CTI Investigational Site 10004
Omaha, Nebraska, United States - CTI Investigational Site 10001
Morristown, New Jersey, United States - (and 78 more...)
|
| 29 |
NCT00962260 |
No longer available |
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease |
|
- Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
|
Expanded Access |
|
|
Industry |
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00962260 |
PB-06-004 |
|
|
|
|
August 19, 2009 |
August 14, 2013 |
|
- La Jolla Village Family Medical Group
La Jolla, California, United States - University of Colorado Denver
Aurora, Colorado, United States - University Research Foundation for Lysosomal Storage Diseases, Inc.
Coral Springs, Florida, United States - (and 12 more...)
|
Create an RSS feed from your search for:
Download the search results for: